FDG PET Biodistribution Patterns of Patients on GLP-1 Therapies

PURPOSE: The use of glucagon-like peptide-1 (GLP-1) therapies continues to increase, but there is limited literature on their effect on fluorodeoxyglucose (FDG) biodistribution and minimal society guidelines. This study presents observations on a cohort of findings associated with GLP-1 use among patients undergoing oncologic FDG PET/CT, with attention to factors that may complicate image interpretation. MATERIALS AND METHODS: This retrospective observational study included 116 adult patients from a single academic center who reported use of a GLP-1. Medical information and demographic information were compiled, and images were analyzed for abnormal biodistribution. Statistical analysis was performed to determine association between these factors and atypical uptake. RESULTS: This study found areas of altered FDG biodistribution in 75.9% (88/116) of patients with uptake noted in the esophagus, small intestines, large intestines, and muscles. Muscle uptake was seen in 21.6% of patients including one patient whose scan was considered nondiagnostic. There was no significant association between muscle uptake and age, sex, BMI, time since last GLP-1 dose, NPO time, blood glucose level, individual GLP-1 medications, insulin usage, metformin usage, other antidiabetic drug usage, systemic steroid usage, or GI symptoms. However, there was a significant association with gastric solid contents (p value 0.01). CONCLUSIONS: This observational study found that patients using GLP-1 therapies exhibit multiple areas of altered biodistribution. Notably, increased muscle uptake had a statistically significant association with concomitant gastric solid contents. There was no association with fasting time (which ranged from 6 to 24 h in our sample). As patients were often on other medications, including other medications for diabetes, uptake may be related to a combination of factors. Further studies are needed to delve into the causes of altered biodistribution on FDG PET/CT performed on patients taking GLP-1s, with close attention to patients with muscle uptake, to inform future guidelines on image interpretation and patient preparation.

Authors

Institutions

Publication Details

Journal
Molecular Imaging and Biology
Published
2026-11-16
DOI
https://doi.org/10.1007/s11307-026-02146-0
Primary Topic
Medical Imaging Techniques and Applications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FDG PET Biodistribution Patterns of Patients on GLP-1 Therapies

Brandon Simon, Charisma DeSai, Charlotte DeGeorge
Molecular Imaging and Biology
Medical Imaging Techniques and Applications
article

FDG PET Biodistribution Patterns of Patients on GLP-1 Therapies

Brandon Simon, Charisma DeSai, Charlotte DeGeorge
article en

Abstract

PURPOSE: The use of glucagon-like peptide-1 (GLP-1) therapies continues to increase, but there is limited literature on their effect on fluorodeoxyglucose (FDG) biodistribution and minimal society guidelines. This study presents observations on a cohort of findings associated with GLP-1 use among patients undergoing oncologic FDG PET/CT, with attention to factors that may complicate image interpretation. MATERIALS AND METHODS: This retrospective observational study included 116 adult patients from a single academic center who reported use of a GLP-1. Medical information and demographic information were compiled, and images were analyzed for abnormal biodistribution. Statistical analysis was performed to determine association between these factors and atypical uptake. RESULTS: This study found areas of altered FDG biodistribution in 75.9% (88/116) of patients with uptake noted in the esophagus, small intestines, large intestines, and muscles. Muscle uptake was seen in 21.6% of patients including one patient whose scan was considered nondiagnostic. There was no significant association between muscle uptake and age, sex, BMI, time since last GLP-1 dose, NPO time, blood glucose level, individual GLP-1 medications, insulin usage, metformin usage, other antidiabetic drug usage, systemic steroid usage, or GI symptoms. However, there was a significant association with gastric solid contents (p value 0.01). CONCLUSIONS: This observational study found that patients using GLP-1 therapies exhibit multiple areas of altered biodistribution. Notably, increased muscle uptake had a statistically significant association with concomitant gastric solid contents. There was no association with fasting time (which ranged from 6 to 24 h in our sample). As patients were often on other medications, including other medications for diabetes, uptake may be related to a combination of factors. Further studies are needed to delve into the causes of altered biodistribution on FDG PET/CT performed on patients taking GLP-1s, with close attention to patients with muscle uptake, to inform future guidelines on image interpretation and patient preparation.

Molecular Imaging and Biology
The University of Texas MD Anderson Cancer Center (US), Washington University in St. Louis (US)
University of Texas MD Anderson Cancer Center
Good health and well-being
Medical Imaging Techniques and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon